EndoLogic

About EndoLogic

The mission of EndoLogic LLC is to design, develop, and market new products to treat gastrointestinal diseases. The company has developed a series of medical device products for the removal of colon polyps and foreign bodies. 510K applications are being prepared for submission to the U.S. Food and Drug Administration for review. The company has acquired renzapride, a 5HT4 agonist and 5HT3 antagonist, to develop it for the treatment of gastroparesis, a poorly-met medical need and for other gastrointestinal indications. The company’s founders are Dr. Zamir S. Brelvi, a U.S. trained gastroenterologist and academic researcher with a vast experience in endoscopic procedures and device development, and Dr. Kamal Dutta. Dr. Dutta, a pelvic surgeon, has more than 30 years of experience in research and development of pharmaceutical products and medical devices.
YEAR FOUNDED:
1992
LEADERSHIP:
Founders: Zamir S. Brelvi and Kamal Dutta
Founder and CEO: Zamir S. Brelvi
PRODUCTS:
All Products